Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$56.60
1.192.15%
al cierre: -
$56.65
0.050.09%
After hour: 7:42 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
CRISPR Therapeutics AG ha un obiettivo di prezzo di consenso pari a $71, stabilito in base alle ultime valutazioni degli analisti di 26. Le ultime 3 valutazioni degli analisti sono state rilasciate da HC Wainwright & Co., Barclays y Chardan Capital il agosto 7, 2025, agosto 6, 2025 y agosto 5, 2025. Con un obiettivo di prezzo medio di $72.67 tra le HC Wainwright & Co., Barclays y Chardan Capital, c'è un implicito 28.27% upside per CRISPR Therapeutics AG da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
HC Wainwright & Co.
Barclays
Chardan Capital
RBC Capital
B of A Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para CRISPR Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/07/2025 | 41.22% | HC Wainwright & Co. | $65 → $80 | Maintains | Buy | |||
08/06/2025 | -1.15% | Barclays | $42 → $56 | Maintains | Equal-Weight | |||
08/05/2025 | 44.75% | Chardan Capital | $82 → $82 | Maintains | Buy | |||
08/05/2025 | -25.86% | RBC Capital | $38 → $42 | Maintains | Sector Perform | |||
07/22/2025 | 37.69% | B of A Securities | $79 → $78 | Maintains | Buy | |||
07/08/2025 | 42.98% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
06/27/2025 | -20.56% | Clear Street | → $45 | Downgrade | Buy → Hold | |||
06/27/2025 | 85.35% | Piper Sandler | $105 → $105 | Reiterates | Overweight → Overweight | |||
06/27/2025 | 51.81% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
06/27/2025 | 14.74% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/26/2025 | 42.98% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
06/26/2025 | 44.75% | Chardan Capital | $82 → $82 | Maintains | Buy | |||
05/21/2025 | 51.81% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
05/20/2025 | 42.98% | Needham | $81 → $81 | Reiterates | Buy → Buy | |||
05/20/2025 | 14.74% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
05/09/2025 | -25.86% | Barclays | $56 → $42 | Maintains | Equal-Weight | |||
05/08/2025 | -17.03% | Goldman Sachs | $53 → $47 | Maintains | Neutral | |||
05/07/2025 | 42.98% | Needham | $84 → $81 | Maintains | Buy | |||
05/07/2025 | 44.75% | Chardan Capital | $84 → $82 | Maintains | Buy | |||
04/09/2025 | 48.28% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
02/19/2025 | — | Cantor Fitzgerald | — | Reiterates | Neutral → Neutral | |||
02/18/2025 | 44.75% | Citigroup | $89 → $82 | Maintains | Buy | |||
02/14/2025 | -43.51% | Morgan Stanley | $30 → $32 | Maintains | Underweight | |||
02/14/2025 | 74.76% | Evercore ISI Group | $60 → $99 | Upgrade | In-Line → Outperform | |||
02/13/2025 | 0.62% | Goldman Sachs | $66 → $57 | Maintains | Neutral | |||
02/13/2025 | 51.81% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
02/13/2025 | -13.5% | Stifel | $53 → $49 | Maintains | Hold | |||
02/13/2025 | 14.74% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
02/13/2025 | 48.28% | Chardan Capital | $94 → $84 | Maintains | Buy | |||
02/12/2025 | 111.83% | Truist Securities | $100 → $120 | Maintains | Buy | |||
02/12/2025 | -15.27% | RBC Capital | $53 → $48 | Maintains | Sector Perform | |||
02/12/2025 | 48.28% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
02/12/2025 | -1.15% | Barclays | $55 → $56 | Maintains | Equal-Weight | |||
02/03/2025 | 14.74% | HC Wainwright & Co. | → $65 | Initiates | → Buy | |||
01/14/2025 | 48.28% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
01/07/2025 | 50.04% | B of A Securities | $98 → $85 | Maintains | Buy | |||
12/20/2024 | 51.81% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
12/10/2024 | 65.93% | Chardan Capital | $94 → $94 | Maintains | Buy | |||
11/06/2024 | -6.44% | RBC Capital | $53 → $53 | Reiterates | Sector Perform → Sector Perform | |||
11/06/2024 | -2.91% | Barclays | $59 → $55 | Maintains | Equal-Weight | |||
11/06/2024 | 48.28% | Needham | $84 → $84 | Reiterates | Buy → Buy | |||
10/04/2024 | -6.44% | RBC Capital | $60 → $53 | Maintains | Sector Perform | |||
08/12/2024 | 76.52% | Truist Securities | $120 → $100 | Maintains | Buy | |||
08/08/2024 | — | Cantor Fitzgerald | — | Reiterates | → Neutral | |||
08/06/2024 | 4.15% | Stifel | $60 → $59 | Maintains | Hold | |||
08/06/2024 | 4.15% | Barclays | $67 → $59 | Maintains | Equal-Weight | |||
08/06/2024 | 5.91% | RBC Capital | $66 → $60 | Maintains | Sector Perform | |||
08/06/2024 | 65.93% | Chardan Capital | $112 → $94 | Maintains | Buy | |||
08/06/2024 | 48.28% | Needham | $88 → $84 | Maintains | Buy | |||
06/28/2024 | — | Guggenheim | — | Assumes | → Neutral | |||
06/27/2024 | 55.34% | Needham | $88 → $88 | Reiterates | Buy → Buy | |||
06/17/2024 | 85.35% | Piper Sandler | $105 → $105 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 55.34% | Needham | $88 → $88 | Reiterates | Buy → Buy | |||
05/23/2024 | 48.28% | Citigroup | $89 → $84 | Maintains | Buy | |||
05/10/2024 | 67.7% | Oppenheimer | $102 → $95 | Maintains | Outperform | |||
05/09/2024 | 51.81% | JMP Securities | $86 → $86 | Reiterates | Market Outperform → Market Outperform | |||
05/09/2024 | 14.74% | Wells Fargo | $70 → $65 | Maintains | Equal-Weight | |||
05/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Neutral | |||
05/09/2024 | 18.27% | Barclays | $80 → $67 | Maintains | Equal-Weight | |||
05/09/2024 | 55.34% | Needham | $90 → $88 | Maintains | Buy | |||
05/09/2024 | -8.21% | Baird | $46 → $52 | Maintains | Neutral | |||
04/18/2024 | 57.11% | Citigroup | $88 → $89 | Maintains | Buy | |||
04/11/2024 | 58.87% | Needham | $90 → $90 | Reiterates | Buy → Buy | |||
03/06/2024 | 74.76% | Mizuho | $82 → $99 | Maintains | Buy | |||
02/26/2024 | -15.27% | Morgan Stanley | $46 → $48 | Maintains | Underweight | |||
02/22/2024 | 16.5% | RBC Capital | $57 → $66 | Maintains | Sector Perform | |||
02/22/2024 | 23.57% | Wells Fargo | $55 → $70 | Maintains | Equal-Weight | |||
02/22/2024 | 41.22% | Barclays | $61 → $80 | Maintains | Equal-Weight | |||
02/22/2024 | 97.71% | Chardan Capital | $110 → $112 | Maintains | Buy | |||
02/21/2024 | 58.87% | Needham | $88 → $90 | Maintains | Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
12/11/2023 | 0.62% | RBC Capital | $50 → $57 | Maintains | Sector Perform | |||
12/11/2023 | 182.44% | Truist Securities | $220 → $160 | Maintains | Buy | |||
12/11/2023 | 7.68% | Barclays | $56 → $61 | Maintains | Equal-Weight | |||
12/11/2023 | -47.04% | TD Cowen | → $30 | Downgrade | Market Perform → Underperform | |||
12/11/2023 | 41.22% | JMP Securities | $74 → $80 | Maintains | Market Outperform | |||
12/11/2023 | 55.34% | Needham | $85 → $88 | Maintains | Buy | |||
12/08/2023 | 288.35% | Truist Securities | → $220 | Reiterates | Buy → Buy | |||
12/08/2023 | 44.75% | Mizuho | → $82 | Reiterates | Buy → Buy | |||
12/05/2023 | 30.63% | JMP Securities | → $74 | Reiterates | Market Outperform → Market Outperform | |||
11/13/2023 | -25.86% | Morgan Stanley | $43 → $42 | Maintains | Underweight | |||
11/07/2023 | -11.74% | RBC Capital | $55 → $50 | Maintains | Sector Perform | |||
11/07/2023 | 50.04% | Needham | $88 → $85 | Maintains | Buy | |||
11/01/2023 | 55.34% | Needham | → $88 | Reiterates | Buy → Buy | |||
10/30/2023 | 55.34% | Needham | → $88 | Reiterates | Buy → Buy | |||
10/17/2023 | — | Cantor Fitzgerald | — | Downgrade | Overweight → Neutral | |||
09/27/2023 | 44.75% | Mizuho | → $82 | Initiates | → Buy | |||
08/18/2023 | 23.57% | Citigroup | → $70 | Upgrade | Neutral → Buy | |||
08/17/2023 | 23.57% | Citigroup | → $70 | Upgrade | Neutral → Buy | |||
08/14/2023 | -24.1% | Morgan Stanley | $42 → $43 | Maintains | Underweight | |||
08/10/2023 | 80.05% | Oppenheimer | → $102 | Reiterates | Outperform → Outperform | |||
08/08/2023 | 11.21% | Credit Suisse | $62 → $63 | Maintains | Neutral | |||
08/08/2023 | 32.39% | EF Hutton | → $75 | Reiterates | Buy → Buy | |||
08/08/2023 | 55.34% | Needham | → $88 | Reiterates | Buy → Buy | |||
08/08/2023 | 94.17% | Chardan Capital | $123 → $110 | Maintains | Buy | |||
07/25/2023 | 30.63% | JMP Securities | → $74 | Reiterates | Market Outperform → Market Outperform | |||
06/09/2023 | 55.34% | Needham | $82 → $88 | Reiterates | Buy → Buy | |||
06/09/2023 | 30.63% | JMP Securities | $70 → $74 | Maintains | Market Outperform | |||
06/09/2023 | 32.39% | EF Hutton | → $75 | Reiterates | → Buy | |||
06/01/2023 | 12.97% | Barclays | $61 → $64 | Maintains | Equal-Weight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de CRISPR Therapeutics (CRSP)?
El último precio objetivo de CRISPR Therapeutics (NASDAQ:CRSP) fue comunicado por HC Wainwright & Co. el agosto 7, 2025. La firma de analistas fijó un precio objetivo para $80.00 que espera CRSP a rise dentro de 12 meses (un posible 41.22% upside). 42 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre CRISPR Therapeutics (CRSP)?
La última calificación de analistas para CRISPR Therapeutics (NASDAQ:CRSP) fue proporcionada por HC Wainwright & Co., y CRISPR Therapeutics mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de CRISPR Therapeutics (CRSP)?
La última revisión al alza de CRISPR Therapeutics AG se produjo en febrero 14, 2025, cuando Evercore ISI Group elevó su precio objetivo a $99. Evercore ISI Group anteriormente tenía an in-line para CRISPR Therapeutics AG.
¿Cuándo fue la última revisión a la baja de CRISPR Therapeutics (CRSP)?
La última revisión a la baja de CRISPR Therapeutics AG se produjo en junio 27, 2025, cuando Clear Street cambió su precio objetivo de N/A a $45 para CRISPR Therapeutics AG.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para CRISPR Therapeutics (CRSP)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de CRISPR Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de CRISPR Therapeutics se registró el agosto 7, 2025, por lo que la próxima calificación estará disponible en torno al agosto 7, 2026.
¿Es correcta la calificación de los analistas sobre CRISPR Therapeutics (CRSP)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de CRISPR Therapeutics (CRSP) fue un mantuvo con un precio objetivo de $65.00 a $80.00. El precio actual al que cotiza CRISPR Therapeutics (CRSP) es de $56.65, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.